HORIZON THERAPEUTICS PUBLIC PLC stock forecast: up to 113.28 USD HZNP stock price prognosis
Forecast for Fri 17 Nov 2023 price
HORIZON THERAPEUTICS PUBLIC PLC stock price forecast for further price development up to 2.96% (time horizon: 1 day) and price target of 113.28 USD. Positive news sentiment. Short-term (time horizon: 2 weeks) HORIZON THERAPEUTICS PUBLIC PLC share price prediction for 2023-11-17 with daily closed price projections
News <--> Close correlation for next day influence (-0.10)
Earnings per share
On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.
Summerized Form 10-K with GPT-2
We believe science and compassion must work together to transform lives. Our website address is www.horizontherapeutics.com. We continue to anticipate the disruption could last through the first quarter of 2021. It is therefore critical for patients to maintain therapy. We also have marketing rights to PROCYSBI in Asia. 6) We market QUINSAIR in Canada. 7) Outside the United States, RAYOS is sold and marketed as LODOTRA. See "Impact of COVID-19" above for further information. 10 RAVICTI competes with older-generation nitrogen scavenger medicines. Older therapies require administration of medicine every six hours. Cystagon is PROCYSBI's primary competitor. As a result, the immune system is weakened. We estimate that there are approximately 1,600 patients with CGD in the United States. We have retained our rights to BUPHENYL in North America. We focus our promotion of RAYOS on rheumatology indications, including RA and PMR. Under these amendments, our rights to LODOTRA in Europe were transferred to Vectura. The primary endpoint for both trials will be FVC. In addition, it has the potential for subcutaneous dosing. In severe cases, respiratory muscles may be compromised. Inflammation and destruction of these glands lead to dry eye and dry mouth. There are currently no treatments approved for Sjögren's syndrome. Targeting this pathway with VIB4920 may reduce inflammation and tissue damage. We may also terminate the agreement within nine months written notice to Roche. If not otherwise invalidated, those patents expire between 2023 and 2030. ACTIMMUNE We have licenses to U.S. patents covering ACTIMMUNE. The FDA does not regulate the behavior of physicians in their choice of treatments. This period may be extended by two further months. France however has a statutory regime similar to the U.S. Sunshine Act. Other legislative changes have also been proposed and adopted since the ACA was enacted. These benefits are paid at 100 percent salary. We also provide equal opportunity in employment to all employees and applicants. 49 Our clinical trials may be affected by COVID-19. It could also lead to an increase in the complexity and cost of tax compliance. Any of these could have a material adverse effect on our business and financial results. Failure can occur at any time during the clinical trial process. A transfer of our ordinary shares may be subject to Irish stamp duty. Litigation may be necessary to defend against these claims.
Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.
Meta analyst score 56.42/100
Good financial position.
Historical view, profit is growing.
Company revenue is not growing faster compared with the
Stock price is under book price value.
Institutional ownership list is based on filling form information
Insider trading for HORIZON THERAPEUTICS PUBLIC PLC
Assets / Liabilities
Bollinger Bollinger Bands for HORIZON THERAPEUTICS PUBLIC PLC can provide the information where the market is moving based on price information.
HORIZON THERAPEUTICS PUBLIC PLC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.
Converting prices to returns HORIZON THERAPEUTICS PUBLIC PLC.
On-Balance Volume information for HORIZON THERAPEUTICS PUBLIC PLC. On-Balance Volume information can be an indicator for bullish or bearish outcome.
Accumulation / Distribution (A/D) indicator information for HORIZON THERAPEUTICS PUBLIC PLC. The indicator identify divergences between price and volume flow.
Aroon Oscillator information for HORIZON THERAPEUTICS PUBLIC PLC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.
Average Directional Index (ADX) information for HORIZON THERAPEUTICS PUBLIC PLC. The index can be used to identify the strengh of a trend.
Moving Average Convergence Divergence (MACD) for HORIZON THERAPEUTICS PUBLIC PLC. The indicator helps to predict trend direction and the momentum of the trend.
Stochastic Oscillator as momentum indicator for HORIZON THERAPEUTICS PUBLIC PLC. The indicator is useful for identifying overbought and oversold levels.
Relative Strength Index (RSI) for HORIZON THERAPEUTICS PUBLIC PLC. RSI is a momentum oscillator that measures the speed and change of price development.
The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period.
Primary usage of the indicator is to identify overbought or oversold signals.
When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30
Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio
Heikin Ashi trading signals are generated based on the Heikin Ashi candles, which are a type of candlestick that smooths out the price action and can help to identify trends.
Heikin Ashi signals can be used to identify both long and short trading opportunities.
The awesome oscillator is a momentum indicator that measures the speed and strength of price movements. It is calculated by subtracting a 34-period simple moving average (SMA) from a 5-period SMA.
The Parabolic SAR indicator is a trend-following indicator that uses a series of dots to indicate when a trend is likely to reverse.
The Parabolic SAR is a lagging indicator, meaning that it does not predict reversals, but rather confirms them after they have already occurred.
The forecast (dashed curve) of the share price performance is based on historical data.
Our forecast model is based on mathematical, statistical methods.
The website offers price forecasts and analysis tools for equities and other securities,
which are exclusively based on the prices of these securities in the past.
Information about these prices is provided to us by third parties. Although we believe,
If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and
correct sequencing of this information.
We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider
any financial data or other data of such issuers with the exception of the past prices of the securities.
Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or
that may be relevant for future security price flows. Investments require additional considerations.
Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor
or the tax implications an investment may have for the investor. Although we believe that
our mathematical models are a tool to try to explore the possibility for future price development
with the help of past performance, such developments are subject to a multitude of different influences.
and therefore not really predictable.
We cannot guarantee the success of any investment you make based on the information published here.
This website is for information purposes only. All information and data on this website cannot be guaranteed
to be accurate,
accuracy, completeness and appropriateness - neither explicit nor implicit.